Comments Supporting FDA Guidance to Modernize Clinical Trial Eligibility Criteria

Restrictive eligibility criteria are the second leading cause preventing patients from enrolling in cancer clinical trials.  FDA recently issued draft guidance encouraging trial sponsors to use a science-based approach that would allow a wider variety of patients to participate in cancer clinical trials.  This community comment letter supports the recommendations made in the guidance documents.